Cocrystal Pharma Files 8-K with Corporate Updates

Ticker: COCP · Form: 8-K · Filed: Dec 1, 2025 · CIK: 1412486

Cocrystal Pharma, INC. 8-K Filing Summary
FieldDetail
CompanyCocrystal Pharma, INC. (COCP)
Form Type8-K
Filed DateDec 1, 2025
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: corporate-disclosure, filing

TL;DR

Cocrystal Pharma filed an 8-K on 12/1/25 detailing corporate info and exhibits.

AI Summary

Cocrystal Pharma, Inc. filed an 8-K on December 1, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's corporate information, including its incorporation in Delaware and principal executive offices located at 19805 N. Creek Parkway, Bothell, WA 98011. The report also lists former company names and dates of name changes.

Why It Matters

This filing provides essential corporate information and disclosures, which are crucial for investors to understand the company's structure and regulatory compliance.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new financial or operational risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to provide a Regulation FD Disclosure and to report Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on December 1, 2025.

In which state is Cocrystal Pharma, Inc. incorporated?

Cocrystal Pharma, Inc. is incorporated in Delaware.

What is the address of Cocrystal Pharma, Inc.'s principal executive offices?

The address of Cocrystal Pharma, Inc.'s principal executive offices is 19805 N. Creek Parkway, Bothell, WA 98011.

What were some of Cocrystal Pharma, Inc.'s former company names?

Cocrystal Pharma, Inc.'s former company names include BIOZONE PHARMACEUTICALS, INC. and International Surf Resorts, Inc.

Filing Stats: 511 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2025-12-01 16:30:29

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cocrystal Pharma, Inc. Date: December 1, 2025 By: /s/ James Martin Name: James Martin Title: Co-Chief Executive Officer and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing